Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Dongying Liao, Yongchao Yu, Qingyun Mei, Ziwei Wang, Xiaojiang Li, Yingjie Jia & Fanming Kong. (2021) Advances in Immunotherapy of Malignant Pleural Mesothelioma. OncoTargets and Therapy 14, pages 4477-4484.
Read now
Read now
Giovanni Luca Ceresoli & Antonio Rossi. (2019) Approved and emerging treatments of malignant pleural mesothelioma in elderly patients. Expert Review of Respiratory Medicine 13:12, pages 1179-1188.
Read now
Read now
Ralph Llewel Sabang, Deepthi Gandhiraj, Michael Fanucchi & Oleg Epelbaum. (2018) Role of bevacizumab in the management of the patient with malignant pleural effusion: more questions than answers. Expert Review of Respiratory Medicine 12:2, pages 87-94.
Read now
Read now
Paolo Baldo & Sara Cecco. (2017) Amatuximab and novel agents targeting mesothelin for solid tumors. OncoTargets and Therapy 10, pages 5337-5353.
Read now
Read now
Articles from other publishers (11)
Joanna Obacz, Henry Yung, Marie Shamseddin, Emily Linnane, Xiewen Liu, Arsalan A. Azad, Doris M. Rassl, David Fairen-Jimenez, Robert C. Rintoul, Marko Z. Nikolić & Stefan J. Marciniak. (2021) Biological basis for novel mesothelioma therapies. British Journal of Cancer 125:8, pages 1039-1055.
Crossref
Crossref
Katharina Sinn, Berta Mosleh & M. Alireza Hoda. (2021) Malignant pleural mesothelioma: recent developments. Current Opinion in Oncology 33:1, pages 80-86.
Crossref
Crossref
Olivia Lauk, Karina Bruestle, Thomas Neuer, Bianca Battilana, Thi Dan Linh Nguyen, Thomas Frauenfelder, Rolf Stahel, Walter Weder, Alessandra Curioni-Fontecedro & Isabelle Opitz. (2020) The Impact on Outcome by Adding Bevacizumab to Standard Induction Chemotherapy Prior to Mesothelioma Surgery: A Retrospective Single Center Analysis. Frontiers in Oncology 10.
Crossref
Crossref
Thomas S. C. Ng, Ravi T. Seethamraju, Raphael Bueno & Ritu R. Gill. (2020) Clinical Implementation of a Free-Breathing, Motion-Robust Dynamic Contrast-Enhanced MRI Protocol to Evaluate Pleural Tumors. American Journal of Roentgenology 215:1, pages 94-104.
Crossref
Crossref
Giovanni L Ceresoli, Joachim G Aerts, Rafal Dziadziuszko, Rodryg Ramlau, Susana Cedres, Jan P van Meerbeeck, Manlio Mencoboni, David Planchard, Antonio Chella, Lucio Crinò, Maciej Krzakowski, Jörn Rüssel, Antonio Maconi, Letizia Gianoncelli & Federica Grosso. (2019) Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. The Lancet Oncology 20:12, pages 1702-1709.
Crossref
Crossref
Yu Sakurai, Akari Kato, Yasuhiro Hida, Junichi Hamada, Nako Maishi, Kyoko Hida & Hideyoshi Harashima. (2019) Synergistic Enhancement of Cellular Uptake With CD44-Expressing Malignant Pleural Mesothelioma by Combining Cationic Liposome and Hyaluronic Acid–Lipid Conjugate. Journal of Pharmaceutical Sciences 108:10, pages 3218-3224.
Crossref
Crossref
Aaron Mansfield, Dennis Wigle & Tobias Peikert. 2019. Caring for Patients with Mesothelioma: Principles and Guidelines. Caring for Patients with Mesothelioma: Principles and Guidelines
187
202
.
Arnaud Scherpereel. 2019. Mesothelioma. Mesothelioma
235
242
.
Bhairavi Tolani, Luis Acevedo, Ngoc Hoang & Biao He. (2018) Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications. International Journal of Molecular Sciences 19:1, pages 238.
Crossref
Crossref
Takeo Tatsuta, Toshiyuki Satoh, Shigeki Sugawara, Akiyoshi Hara & Masahiro Hosono. (2018) Sialic acid-binding lectin from bullfrog eggs inhibits human malignant mesothelioma cell growth in vitro and in vivo. PLOS ONE 13:1, pages e0190653.
Crossref
Crossref
Isabel Corraliza-Gorjón, Beatriz Somovilla-Crespo, Silvia Santamaria, Jose A. Garcia-Sanz & Leonor Kremer. (2017) New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness. Frontiers in Immunology 8.
Crossref
Crossref